University Hospital Innsbruck

Innsbruck 6020

4 studies enrolling now · 6 studies all time

What they study most

Acquired Antithrombin Deficiency, Focal Epilepsy, Focal Onset Seizures, Leukemia, Lymphocytic, Chronic, B-Cell, Locally Advanced or Unresectable Metastatic Breast Cancer, Primary Generalized Tonic-Clonic Seizures, Stage IV Breast Cancer, Tonic-Clonic Seizures

Studies at this site

• A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures — Recruiting now
• A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) — Recruiting now
• Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass — Recruiting now
• An Open-label Study of XEN1101 in Epilepsy — Enrolling by invitation
• Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy — Running, not enrolling
• A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — Completed